Choreo LLC Lowers Stake in Eli Lilly and Company $LLY

Choreo LLC cut its holdings in Eli Lilly and Company (NYSE:LLY) by 3.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 29,104 shares of the company’s stock after selling 1,084 shares during the quarter. Choreo LLC’s holdings in Eli Lilly and Company were worth $31,425,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in LLY. Maryland Capital Advisors Inc. acquired a new position in Eli Lilly and Company in the 4th quarter valued at about $25,000. Vermillion & White Wealth Management Group LLC lifted its position in Eli Lilly and Company by 84.2% during the 3rd quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company’s stock worth $27,000 after acquiring an additional 16 shares during the period. Steph & Co. lifted its position in Eli Lilly and Company by 290.0% during the 3rd quarter. Steph & Co. now owns 39 shares of the company’s stock worth $30,000 after acquiring an additional 29 shares during the period. 10Elms LLP grew its stake in shares of Eli Lilly and Company by 33.3% in the 3rd quarter. 10Elms LLP now owns 40 shares of the company’s stock valued at $31,000 after purchasing an additional 10 shares during the last quarter. Finally, Miller Global Investments LLC purchased a new position in shares of Eli Lilly and Company in the 4th quarter valued at approximately $33,000. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly received another buy rating tied to its newly launched obesity pill, which analysts expect to be a global bestseller — this supports revenue upside from weight‑loss therapies. Eli Lilly Stock (LLY) Gets Another Buy Rating as Its Obesity Pill Hits the Market
• Positive Sentiment: Lilly agreed to acquire CrossBridge Bio for up to $300M, adding preclinical ADC technology to bolster oncology pipeline optionality and long‑term growth prospects. Lilly to acquire CrossBridge Bio for up to $300m
• Positive Sentiment: Distribution and access expand as digital care platform Shed adds Foundayo™ (Lilly’s oral GLP‑1 for weight management), which can help broaden patient uptake beyond specialty clinics. Shed Adds Foundayo™ to Its Platform, Expanding Oral GLP-1 Access for Patients Nationwide
• Positive Sentiment: Lilly is licensing its TuneLab AI platform to partners (e.g., Vasa Therapeutics), highlighting additional revenue streams and R&D leverage from proprietary AI tools. Vasa Therapeutics Partners with Lilly TuneLab to Power AI/ML-Driven CAMKII Inhibitor Platform
• Neutral Sentiment: Macro/valuation commentary remains mixed — some bullish, long‑term price targets (e.g., Forbes piece on LLY to $2,000) reflect confidence in blockbuster drugs but are speculative. LLY Stock To $2,000?
• Neutral Sentiment: Market reports note the stock is down today despite broader market gains — a short‑term price action update for traders. Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know
• Negative Sentiment: Competitive risk is rising: Novo Nordisk’s new partnership with OpenAI to accelerate drug discovery reinforces its capability to close gaps in the weight‑loss market and may pressure Lilly’s market share and investor sentiment. NVO Inks Deal With OpenAI for Speedy Drug Discovery Globally, Stock Up

Eli Lilly and Company Price Performance

LLY stock opened at $905.73 on Thursday. The firm has a 50 day moving average of $976.09 and a 200-day moving average of $979.89. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,133.95. The company has a current ratio of 1.58, a quick ratio of 1.19 and a debt-to-equity ratio of 1.54. The company has a market cap of $855.75 billion, a price-to-earnings ratio of 39.47, a PEG ratio of 1.07 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $7.48 by $0.06. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The company had revenue of $19.29 billion during the quarter, compared to the consensus estimate of $17.85 billion. During the same period last year, the firm earned $5.32 EPS. The company’s revenue for the quarter was up 42.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. As a group, equities analysts expect that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on LLY shares. BMO Capital Markets restated an “outperform” rating and set a $1,300.00 price target on shares of Eli Lilly and Company in a research note on Thursday, February 5th. Morgan Stanley lifted their price objective on shares of Eli Lilly and Company from $1,313.00 to $1,327.00 and gave the company an “overweight” rating in a research report on Friday, April 10th. Weiss Ratings reissued a “buy (b)” rating on shares of Eli Lilly and Company in a research note on Friday, March 27th. Daiwa Securities Group raised their target price on shares of Eli Lilly and Company from $1,230.00 to $1,250.00 and gave the stock a “buy” rating in a research note on Wednesday, February 18th. Finally, Berenberg Bank lifted their target price on shares of Eli Lilly and Company from $950.00 to $1,050.00 and gave the company a “hold” rating in a report on Thursday, February 19th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and a consensus target price of $1,224.59.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.